New shot could simplify schizophrenia treatment
NCT ID NCT06253546
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 1 trial tests a single injection of TV-44749, an extended-release form of olanzapine, in Chinese adults with stable schizophrenia. The study aims to check safety, tolerability, and how the drug moves through the body. Participants receive one of three doses of the injection or continue oral olanzapine for comparison.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TV-44749 (extended-release injectable olanzapine)
What this could lead to
If successful, this could provide a longer-lasting treatment option for schizophrenia, potentially reducing the need for daily pills.
What could go wrong
This is an early phase 1 trial with only 24 participants, so safety and effectiveness are not yet established. Side effects may occur, and results may not apply to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Teva Investigational Site 88046
Shanghai, 200030, China
-
Teva Investigational Site 88047
Guangzhou, 510370, China
-
Teva Investigational Site 88048
Beijing, 100191, China
-
Teva Investigational Site 88049
Beijing, 100088, China
-
Teva Investigational Site 88050
Wuhan, 430022, China
-
Teva Investigational Site 88056
Xi'an, 710061, China